igc is developing a product portfolio of phytocannabinoid-based therapies through leading edge research for the treatment of a wide range of therapeutic indications. these include neuropathic and cancer pain, epilepsy, end of life supportive care, adjunctive supportive therapies of chronic neurological and oncological diagnosis, which are life altering or life threatening our mission is to treat pain, ptsd, seizures, cachexia, chronic and terminal neurological and oncological diagnoses, and other life altering conditions with phytocannabinoid-based treatments
Company profile
Ticker
IGC
Exchange
Website
CEO
Ram Mukunda
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
India Globalization Capital, Inc.
SEC CIK
Corporate docs
Subsidiaries
holding company • IGCare, LLC • IGC Pharma, LLC • Holi Hemp, LLC • Sunday Seltzer, LLC • SAN Holdings, LLC • IGC Pharma SAS • Techni Bharathi Private Limited • India Mining and Trading Private Limited • IGC Materials Private Limited ...
IRS number
202760393
IGC stock data
Latest filings (excl ownership)
S-3
Shelf registration
17 Apr 24
8-K
IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation
5 Apr 24
8-K
IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock
27 Mar 24
8-K
Entry into a Material Definitive Agreement
21 Mar 24
424B5
Prospectus supplement for primary offering
21 Mar 24
8-K
Departure of Directors or Certain Officers
13 Mar 24
10-Q
2024 Q3
Quarterly report
14 Feb 24
424B5
Prospectus supplement for primary offering
31 Jan 24
EFFECT
Notice of effectiveness
9 Jan 24
CORRESP
Correspondence with SEC
4 Jan 24
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Mar 23 | Mar 22 | Mar 21 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 3.03 mm | 3.03 mm | 3.03 mm | 3.03 mm | 3.03 mm | 3.03 mm |
Cash burn (monthly) | (no burn) | 299.75 k | 830.33 k | 912.25 k | 539.33 k | 520.92 k |
Cash used (since last report) | n/a | 2.05 mm | 5.68 mm | 6.24 mm | 3.69 mm | 3.57 mm |
Cash remaining | n/a | 974.13 k | -2.66 mm | -3.22 mm | -665.89 k | -539.82 k |
Runway (months of cash) | n/a | 3.2 | -3.2 | -3.5 | -1.2 | -1.0 |
Institutional ownership, Q2 2023
4.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 25 |
Opened positions | 2 |
Closed positions | 1 |
Increased positions | 4 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 759.54 mm |
Total shares | 2.65 mm |
Total puts | 18.50 k |
Total calls | 44.10 k |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 755.79 k | $235.50 mm |
Vanguard | 646.54 k | $201.46 mm |
Geode Capital Management | 302.14 k | $94.15 mm |
STT State Street | 184.11 k | $57.37 mm |
Renaissance Technologies | 162.71 k | $51.00 k |
Dearborn Partners | 116.71 k | $36.37 mm |
Susquehanna International | 75.16 k | $23.42 mm |
NTRS Northern Trust | 71.36 k | $22.24 mm |
Bridgeway Capital Management | 69.00 k | $21.50 mm |
GS Goldman Sachs | 65.51 k | $20.41 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
13 Mar 24 | Terry L Lierman | OPTIONS Common Stock | Grant | Acquire A | No | No | 0.3 | 150,000 | 45.00 k | 150,000 |
13 Mar 24 | Prins Richard K | Common Stock | Option exercise | Acquire M | No | No | 0 | 28,500 | 0.00 | 1,242,917 |
13 Mar 24 | Prins Richard K | Common Stock | Option exercise | Acquire M | No | No | 0 | 42,750 | 0.00 | 1,214,417 |
13 Mar 24 | Prins Richard K | Common Stock | Option exercise | Acquire M | No | No | 0 | 100,000 | 0.00 | 1,171,667 |
13 Mar 24 | Prins Richard K | Common Stock | Option exercise | Acquire M | No | No | 0 | 58,333 | 0.00 | 1,071,667 |
13 Mar 24 | Prins Richard K | Common Stock | Option exercise | Acquire M | No | No | 0 | 100,000 | 0.00 | 1,013,334 |
13 Mar 24 | Prins Richard K | RSU Common Stock | Grant | Acquire A | No | No | 0 | 175,000 | 0.00 | 175,000 |
13 Mar 24 | Prins Richard K | RSU Common Stock | Grant | Acquire A | No | No | 0 | 210,000 | 0.00 | 210,000 |
13 Mar 24 | Prins Richard K | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 71,250 | 0.00 | 213,750 |
13 Mar 24 | Prins Richard K | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 100,000 | 0.00 | 200,000 |
News
'Cannabis Seizures At Checkpoints By U.S.-Mexico Border Frustrates State-Authorized Pot Industry' - Audacy Citing AP
19 Apr 24
12 Health Care Stocks Moving In Tuesday's After-Market Session
16 Apr 24
IGC Pharma Says Cannabinoid-Based Drug Candidate Provides Fast Relief With Fewer Side Effects For Alzheimer's-Associated Agitation
16 Apr 24
Who's Who In Cannabis: Latest Executive Changes You Should Know About
15 Apr 24
'Marijuana Companies Ask Federal Court To Set Oral Arguments On DOJ Claim That Cannabis 'Tourism' Justifies Prohibition Enforcement' - Marijuana Moment
15 Apr 24
Press releases
IGC-AD1's Interim Phase 2 Data Show a Reduction in Alzheimer's Agitation at Week Two
16 Apr 24
IGC Pharma Adds Advisor in Artificial Intelligence
9 Apr 24
IGC Pharma Releases Positive Interim Analysis Of Its Ongoing Phase 2 Trial In Alzheimer's Research
3 Apr 24
IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock
26 Mar 24
IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer's Agitation
20 Mar 24